Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer

作     者：Han Li Shumin Yuan Han Wu Yajie Wang Yichen Ma Xiance Tang Xiaomin Fu Lingdi Zhao Benling Xu Tiepeng Li Peng Qin Hongqin You Lu Han Zibing Wang 

作者机构：Department of ImmunotherapyThe Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer HospitalZhengzhouChina Department of OncologyQilu Hospital of Shandong UniversityJinanChina Biotherapy CenterThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina Nanchang University Queen Mary SchoolNanchangChina The First Clinical Medical College of Xinjiang Medical UniversityUrumqiChina Department of Medical AffairsThe Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer HospitalZhengzhouChina 

出 版 物：《Cancer Innovation》 (肿瘤学创新（英文）)

年 卷 期：2024年第3卷第6期

页      面：76-85页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：National Natural Science Foundation of China,Grant/Award Number:81972690 Medical Science and Technology Research Project of Health Commission of Henan Province,Grant/Award Number:YXKC2021007 

主　　题：combination immunotherapy extensive‐stage small cell lung cancer immune checkpoint inhibitors low‐dose antiangiogenic drugs 

摘      要：Background:This study evaluated the efficacy and safety of low‐dose anlotinib combined with immune checkpoint inhibitors as second‐line or later treatment for extensive‐stage small cell lung cancer(ES‐SCLC).Methods:The study included 42 patients with ES‐SCLC who were treated with low‐dose anlotinib combined with programmed cell death protein 1/programmed cell death‐ligand 1 inhibitors at Henan Cancer Hospital between March 2019 and August *** retrospectively analyzed the efficacy and safety data for these *** assessed included progression‐free survival(PFS),overall survival(OS),the overall response rate(ORR),the disease control rate(DCR),and adverse events(AEs).Prognostic factors were identified in univariate and multivariate ***:Median PFS was 11.0 months(95%CI:7.868–14.132)and median OS was 17.3 months(95%CI:11.517–23.083).The ORR was 28.5%and the DCR was 95.2%.Treatment‐related AEs were noted in 27 patients(64.3%),the most common of which was thyroid dysfunction(26.2%).Grade 3/4 treatmentrelated AEs were observed in two patients(4.8%).Conclusions:A combination of low‐dose anlotinib and immune checkpoint inhibitors as second‐line or later treatment for ES‐SCLC may achieve longer PFS and OS and have manageable AEs.